Td Asset Management Inc C4 Therapeutics, Inc. Transaction History

Td Asset Management Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 08, 2024	SELL	$5.3 - $11.0 $8,480 - $17,600	-1,600 Reduced 1.69%	92,800 $758,000
Q4 2023 Feb 12, 2024	BUY	$1.18 - $6.03 $111,392 - $569,232	94,400 New	94,400 $533,000
Q3 2022 Nov 07, 2022	SELL	$8.03 - $12.77 $53,800 - $85,559	-6,700 Reduced 12.15%	48,453 $414,000
Q2 2022 Aug 04, 2022	SELL	$5.06 - $26.46 $263,120 - $1.38 Million	-52,000 Reduced 48.53%	55,153 $416,000
Q1 2022 May 10, 2022	BUY	$19.99 - $33.23 $15,991 - $26,583	800 Added 0.75%	107,153 $2.6 Million
Q4 2021 Feb 10, 2022	BUY	$29.39 - $46.86 $193,974 - $309,276	6,600 Added 6.62%	106,353 $3.43 Million
Q3 2021 Nov 09, 2021	BUY	$35.91 - $50.5 $140,049 - $196,950	3,900 Added 4.07%	99,753 $4.46 Million
Q2 2021 Aug 11, 2021	BUY	$30.39 - $42.18 $890,427 - $1.24 Million	29,300 Added 44.03%	95,853 $4.14 Million
Q1 2021 May 14, 2021	BUY	$31.96 - $46.5 $1.62 Million - $2.36 Million	50,772 Added 321.73%	66,553 $2.46 Million
Q4 2020 Feb 16, 2021	BUY	$22.8 - $37.05 $359,806 - $584,686	15,781 New	15,781 $523,000

122

53.8M

331K

145K

Ticker CCCC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,913,800
Market Cap $293M
Description
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting ...

Get notified when there are updates to the investment portfolio of Td Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Td Asset Management Inc with notifications on news.